메뉴 건너뛰기




Volumn 48, Issue 6, 2013, Pages 525-537

Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: VI. Executive summary

Author keywords

pharmacodynamics; pharmacokinetics; Pseudomonas aeruginosa

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOGLYCOSIDE DERIVATIVE; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; COLISTIMETHATE; COLISTIN; DORIPENEM; GENTAMICIN; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE; TIMENTIN; TOBRAMYCIN;

EID: 84878313752     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.22757     Document Type: Article
Times cited : (26)

References (83)
  • 1
    • 0029934215 scopus 로고    scopus 로고
    • Management of pulmonary disease in patients with cystic fibrosis
    • DOI 10.1056/NEJM199607183350307
    • Ramsey BW,. Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med 1996; 335: 179-188. (Pubitemid 26249456)
    • (1996) New England Journal of Medicine , vol.335 , Issue.3 , pp. 179-188
    • Ramsey, B.W.1
  • 3
    • 33144467144 scopus 로고    scopus 로고
    • Nonpharmacologic airway clearance therapies: ACCP evidence-based clinical practice guidelines
    • DOI 10.1378/chest.129.1-suppl.250S
    • McCool FD, Rosen MJ,. Nonpharmacologic airway clearance therapies: ACCP evidence-based clinical practice guidelines. Chest 2006; 129: 250S-259S. (Pubitemid 43265229)
    • (2006) Chest , vol.129 , Issue.SUPPL.
    • McCool, F.D.1    Rosen, M.J.2
  • 10
    • 26944446140 scopus 로고    scopus 로고
    • Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis
    • DOI 10.1164/rccm.200502-218OC
    • Saiman L, Anstead M, Mayer-Hamblett N, Lands LC, Kloster M, Hocevar-Trnka J, Goss CH, Rose LM, Burns JL, Marshall BC, et al. Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. Am J Respir Crit Care Med 2005; 172: 1008-1012. (Pubitemid 41476538)
    • (2005) American Journal of Respiratory and Critical Care Medicine , vol.172 , Issue.8 , pp. 1008-1012
    • Saiman, L.1    Mayer-Hamblett, N.2    Campbell, P.3    Marshall, B.C.4
  • 13
    • 84869499744 scopus 로고    scopus 로고
    • Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: I. aztreonam and carbapenems
    • Zobell JT, Waters CD, Young DC, Stockmann C, Ampofo K, Sherwin CM, Spigarelli, MG,. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: I. aztreonam and carbapenems. Pediatr Pulmonol 2012; 47: 1147-1158.
    • (2012) Pediatr Pulmonol , vol.47 , pp. 1147-1158
    • Zobell, J.T.1    Waters, C.D.2    Young, D.C.3    Stockmann, C.4    Ampofo, K.5    Sherwin, C.M.6    Spigarelli, M.G.7
  • 14
    • 84872404132 scopus 로고    scopus 로고
    • Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. cephalosporins and penicillins
    • Zobell JT, Waters CD, Young DC, Stockmann C, Ampofo K, Sherwin CM, Spigarelli, MG,. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. cephalosporins and penicillins. Pediatr Pulmonol 2013; 48: 107-122.
    • (2013) Pediatr Pulmonol , vol.48 , pp. 107-122
    • Zobell, J.T.1    Waters, C.D.2    Young, D.C.3    Stockmann, C.4    Ampofo, K.5    Sherwin, C.M.6    Spigarelli, M.G.7
  • 15
    • 84876497972 scopus 로고    scopus 로고
    • Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones
    • et al. (in press).
    • Stockmann C, et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones. Pediatr Pulmonol 2012 (in press).
    • (2012) Pediatr Pulmonol
    • Stockmann, C.1
  • 20
    • 77950574187 scopus 로고    scopus 로고
    • Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008
    • Emerson J, McNamara S, Buccat AM, Worrell K, Burns JL,. Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008. Pediatr Pulmonol 2010; 45: 363-370.
    • (2010) Pediatr Pulmonol , vol.45 , pp. 363-370
    • Emerson, J.1    McNamara, S.2    Buccat, A.M.3    Worrell, K.4    Burns, J.L.5
  • 22
    • 79952753579 scopus 로고    scopus 로고
    • Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis
    • Sanders DB, Bittner RC, Rosenfeld M, Redding, GJ, Goss CH,. Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis. Pediatr Pulmonol 2011; 46: 393-400.
    • (2011) Pediatr Pulmonol , vol.46 , pp. 393-400
    • Sanders, D.B.1    Bittner, R.C.2    Rosenfeld, M.3    Redding, G.J.4    Goss, C.H.5
  • 24
    • 84856731944 scopus 로고    scopus 로고
    • Incidence and risk factors for pulmonary exacerbation treatment failures in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa
    • Parkins MD, Rendall JC, Elborn JS,. Incidence and risk factors for pulmonary exacerbation treatment failures in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa. Chest 2012; 141: 485-493.
    • (2012) Chest , vol.141 , pp. 485-493
    • Parkins, M.D.1    Rendall, J.C.2    Elborn, J.S.3
  • 26
    • 66149157735 scopus 로고    scopus 로고
    • A survey of once-daily dosage tobramycin therapy in patients with cystic fibrosis
    • Van Meter DJ, Corriveau M, Ahern JW, Lahiri T,. A survey of once-daily dosage tobramycin therapy in patients with cystic fibrosis. Pediatr Pulmonol 2009; 44: 325-329.
    • (2009) Pediatr Pulmonol , vol.44 , pp. 325-329
    • Van Meter, D.J.1    Corriveau, M.2    Ahern, J.W.3    Lahiri, T.4
  • 28
    • 84878325359 scopus 로고    scopus 로고
    • National survey of extended-interval aminoglycoside dosing in pediatric cystic fibrosis pulmonary exacerbations
    • Prescott WA, Jr., National survey of extended-interval aminoglycoside dosing in pediatric cystic fibrosis pulmonary exacerbations. J Pediatr Pharmacol Ther 2011; 16: 262-269.
    • (2011) J Pediatr Pharmacol Ther , vol.16 , pp. 262-269
    • Prescott Jr., W.A.1
  • 29
    • 0023119430 scopus 로고
    • Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration
    • Moore RD, Lietman PS, Smith CR,. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155: 93-99. (Pubitemid 17225088)
    • (1987) Journal of Infectious Diseases , vol.155 , Issue.1 , pp. 93-99
    • Moore, R.D.1    Lietman, P.S.2    Smith, C.R.3
  • 30
    • 0012218658 scopus 로고    scopus 로고
    • Antimicrobial agents: The aminoglycosides
    • Limbird JGHaLE, editor. New York: McGraw-Hill;.
    • Chambers HF,. Antimicrobial agents: The aminoglycosides. In:, Limbird JGHaLE, editor. Goodman and Gilman's the pharmacological basis of therapeutics. New York: McGraw-Hill; 2001. pp 1219-1238.
    • (2001) Goodman and Gilman's the Pharmacological Basis of Therapeutics , pp. 1219-1238
    • Chambers, H.F.1
  • 32
    • 84878282305 scopus 로고    scopus 로고
    • Intermittent and extended-infusion Beta-Lactam utilization in cystic fibrosis
    • (in press).
    • Zobell JT, Young DC, Chatfield BA,. Intermittent and extended-infusion Beta-Lactam utilization in cystic fibrosis. Pediatr Pulmonol 2012 (in press).
    • (2012) Pediatr Pulmonol
    • Zobell, J.T.1    Young, D.C.2    Chatfield, B.A.3
  • 33
    • 13844254908 scopus 로고    scopus 로고
    • Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis - The TOPIC study: A randomised controlled trial
    • DOI 10.1016/S0140-6736(05)17906-9
    • Smyth A, Tan KH, Hyman-Taylor P, Mulheran M, Lewis S, Stableforth D, Prof Knox A,. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis-the TOPIC study: a randomised controlled trial. Lancet 2005; 365: 573-578. (Pubitemid 40247913)
    • (2005) Lancet , vol.365 , Issue.9459 , pp. 573-578
    • Smyth, A.1    Tan, K.H.-V.2    Hyman-Taylor, P.3    Mulheran, M.4    Lewis, S.5    Stableforth, D.6    Knox, A.7
  • 34
    • 0031048805 scopus 로고    scopus 로고
    • Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation
    • DOI 10.1097/00006454-199701000-00033
    • Rubio TT, Miles MV, Lettieri JT, Kuhn RJ, Echols RM, Church DA,. Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation. Pediatr Infect Dis J 1997; 16: 112-117; discussion 123-126. (Pubitemid 27063129)
    • (1997) Pediatric Infectious Disease Journal , vol.16 , Issue.1 , pp. 112-117
    • Rubio, T.T.1    Miles, M.V.2    Lettieri, J.T.3    Kuhn, R.J.4    Echols, R.M.5    Church, D.A.6
  • 35
    • 77953915742 scopus 로고    scopus 로고
    • High dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients
    • Zobell JT, Ampofo K, Cash J, Korgenski K, Chatfield BA,. High dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients. J Cyst Fibros 2010; 9: 280-283.
    • (2010) J Cyst Fibros , vol.9 , pp. 280-283
    • Zobell, J.T.1    Ampofo, K.2    Cash, J.3    Korgenski, K.4    Chatfield, B.A.5
  • 39
    • 0026723491 scopus 로고
    • A comparison of aztreonam and ceftazidime in the treatment of respiratory infections in adults with cystic fibrosis
    • Salh B, Bilton D, Dodd M, Abbot J, Webb K,. A comparison of aztreonam and ceftazidime in the treatment of respiratory infections in adults with cystic fibrosis. Scand J Infect Dis 1992; 24: 215-218.
    • (1992) Scand J Infect Dis , vol.24 , pp. 215-218
    • Salh, B.1    Bilton, D.2    Dodd, M.3    Abbot, J.4    Webb, K.5
  • 40
    • 40649105285 scopus 로고    scopus 로고
    • Efficacy and safety of intravenous meropenem and tobramycin versus ceftazidime and tobramycin in cystic fibrosis
    • DOI 10.1016/j.jcf.2007.07.001, PII S1569199307000926
    • Latzin P, Fehling M, Bauernfeind A, Reinhardt D, Kappler M, Griese M,. Efficacy and safety of intravenous meropenem and tobramycin versus ceftazidime and tobramycin in cystic fibrosis. J Cyst Fibros 2008; 7: 142-146. (Pubitemid 351372759)
    • (2008) Journal of Cystic Fibrosis , vol.7 , Issue.2 , pp. 142-146
    • Latzin, P.1    Fehling, M.2    Bauernfeind, A.3    Reinhardt, D.4    Kappler, M.5    Griese, M.6
  • 41
    • 27144479200 scopus 로고    scopus 로고
    • The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis
    • DOI 10.1378/chest.128.4.2336
    • Blumer JL, Saiman L, Konstan MW, Melnick D,. The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis. Chest 2005; 128: 2336-2346. (Pubitemid 41507577)
    • (2005) Chest , vol.128 , Issue.4 , pp. 2336-2346
    • Blumer, J.L.1    Saiman, L.2    Konstan, M.W.3    Melnick, D.4
  • 42
    • 78650185664 scopus 로고    scopus 로고
    • Suboptimal ciprofloxacin dosing as a potential cause of decreased Pseudomonas aeruginosa susceptibility in children with cystic fibrosis
    • Guillot E, Sermet I, Ferroni A, Chhun S, Pons G, Zahar JR, Jullien V,. Suboptimal ciprofloxacin dosing as a potential cause of decreased Pseudomonas aeruginosa susceptibility in children with cystic fibrosis. Pharmacotherapy 2010; 30: 1252-1258.
    • (2010) Pharmacotherapy , vol.30 , pp. 1252-1258
    • Guillot, E.1    Sermet, I.2    Ferroni, A.3    Chhun, S.4    Pons, G.5    Zahar, J.R.6    Jullien, V.7
  • 43
    • 0031783802 scopus 로고    scopus 로고
    • Drug disposition in cystic fibrosis
    • DOI 10.2165/00003088-199835040-00004
    • Rey E, Treluyer JM, Pons G,. Drug disposition in cystic fibrosis. Clin Pharmacokinet 1998; 35: 313-329. (Pubitemid 28491216)
    • (1998) Clinical Pharmacokinetics , vol.35 , Issue.4 , pp. 313-329
    • Rey, E.1    Treluyer, J.-M.2    Pons, G.3
  • 44
    • 0022117320 scopus 로고
    • Increased dosage requirements of tobramycin and gentamicin for treating Pseudomonas pneumonia in patients with cystic fibrosis
    • Mann HJ, Canafax DM, Cipolle RJ, Daniels CE, Zaske DE, Warwick WJ,. Increased dosage requirements of tobramycin and gentamicin for treating Pseudomonas pneumonia in patients with cystic fibrosis. Pediatr Pulmonol 1985; 1: 238-243.
    • (1985) Pediatr Pulmonol , vol.1 , pp. 238-243
    • Mann, H.J.1    Canafax, D.M.2    Cipolle, R.J.3    Daniels, C.E.4    Zaske, D.E.5    Warwick, W.J.6
  • 45
    • 0023555047 scopus 로고
    • Drug disposition in cystic fibrosis: Progress in understanding pathophysiology and pharmacokinetics
    • Prandota J,. Drug disposition in cystic fibrosis: progress in understanding pathophysiology and pharmacokinetics. Pediatr Infect Dis J 1987; 6: 1111-1126. (Pubitemid 18029589)
    • (1987) Pediatric Infectious Disease Journal , vol.6 , Issue.12 , pp. 1111-1126
    • Prandota, J.1
  • 47
    • 0023205584 scopus 로고
    • High dose treatment with antibiotics in cystic fibrosis - A reappraisal with special reference to the pharmacokinetics of betalactams and new fluoroquinolones in adult CF-patients
    • DOI 10.1007/BF01647751
    • Sorgel F, Stephan U, Wiesemann HG, Gottschalk B, Stehr C, Rey M, Bowing HB, Dominick HC, Geldmacher von Mallinckrodt M,. High dose treatment with antibiotics in cystic fibrosis-a reappraisal with special reference to the pharmacokinetics of beta-lactams and new fluoroquinolones in adult CF-patients. Infection 1987; 15: 385-396. (Pubitemid 17156117)
    • (1987) Infection , vol.15 , Issue.5 , pp. 385-396
    • Sorgel, F.1    Stephan, U.2    Wiesemann, H.G.3    Gottschalk, B.4    Stehr, C.5    Rey, M.6    Bowing, H.B.7    Dominick, H.C.8    Geldmacher Von Mallinckrodt, M.9
  • 48
    • 0031874587 scopus 로고    scopus 로고
    • Clinical pharmacokinetics of antimicrobial drugs in cystic fibrosis
    • DOI 10.1023/A:1008634911114
    • Touw DJ,. Clinical pharmacokinetics, of antimicrobial, drugs in, cystic fibrosis. Pharm World Sci 1998; 20: 149-160. (Pubitemid 28393870)
    • (1998) Pharmacy World and Science , vol.20 , Issue.4 , pp. 149-160
    • Touw, D.J.1
  • 49
    • 0032433579 scopus 로고    scopus 로고
    • Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Current practice and suggestions for future directions
    • DOI 10.2165/00003088-199835060-00003
    • Touw DJ, Vinks AA, Mouton JW, Horrevorts, AM,. Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Current practice and suggestions for future directions. Clin Pharmacokinet 1998; 35: 437-459. (Pubitemid 29010175)
    • (1998) Clinical Pharmacokinetics , vol.35 , Issue.6 , pp. 437-459
    • Touw, D.J.1    Vinks, A.A.T.M.M.2    Mouton, J.W.3    Horrevorts, A.M.4
  • 51
    • 33847753552 scopus 로고    scopus 로고
    • Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis-caution with trough concentrations
    • DOI 10.1016/j.jcf.2006.05.015, PII S1569199306000907
    • Coulthard KP, Peckham DG, Conway SP, Smith CA, Bell J, Turnidge J,. Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis-caution with trough concentrations. J Cyst Fibros 2007; 6: 125-130. (Pubitemid 46381653)
    • (2007) Journal of Cystic Fibrosis , vol.6 , Issue.2 , pp. 125-130
    • Coulthard, K.P.1    Peckham, D.G.2    Conway, S.P.3    Smith, C.A.4    Bell, J.5    Turnidge, J.6
  • 52
    • 0035177895 scopus 로고    scopus 로고
    • Individualising aminoglycoside dosage regimens after therapeutic drug monitoring: Simple or complex pharmacokinetic methods?
    • Tod MM, Padoin C, Petitjean O,. Individualising aminoglycoside dosage regimens after therapeutic drug monitoring: simple or complex pharmacokinetic methods? Clin Pharmacokinet 2001; 40: 803-814. (Pubitemid 33095997)
    • (2001) Clinical Pharmacokinetics , vol.40 , Issue.11 , pp. 803-814
    • Tod, M.M.1    Padoin, C.2    Petitjean, O.3
  • 54
    • 34250632673 scopus 로고    scopus 로고
    • Introduction of quantitative methods in pharmacology and clinical pharmacology: A historical overview
    • DOI 10.1038/sj.clpt.6100248, PII 6100248
    • Atkinson AJ, Jr., Lalonde RL,. Introduction of quantitative methods in pharmacology and clinical pharmacology: a historical overview. Clin Pharmacol Ther 2007; 82: 3-6. (Pubitemid 46944206)
    • (2007) Clinical Pharmacology and Therapeutics , vol.82 , Issue.1 , pp. 3-6
    • Atkinson Jr., A.J.1    Lalonde, R.L.2
  • 56
    • 34250658781 scopus 로고    scopus 로고
    • Getting the dose right": Facts, a blueprint, and encouragements
    • Peck CC, Cross JT,. " Getting the dose right": facts, a blueprint, and encouragements. Clin Pharmacol Ther 2007; 82: 12-14.
    • (2007) Clin Pharmacol Ther , vol.82 , pp. 12-14
    • Peck, C.C.1    Cross, J.T.2
  • 57
    • 18844452358 scopus 로고    scopus 로고
    • Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: An update
    • DOI 10.1093/jac/dki079
    • Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL,. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother 2005; 55: 601-607. (Pubitemid 40691835)
    • (2005) Journal of Antimicrobial Chemotherapy , vol.55 , Issue.5 , pp. 601-607
    • Mouton, J.W.1    Dudley, M.N.2    Cars, O.3    Derendorf, H.4    Drusano, G.L.5
  • 58
    • 13244281964 scopus 로고    scopus 로고
    • Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: The minimum inhibitory concentration versus stationary concentration
    • DOI 10.2165/00003088-200544020-00005
    • Mouton JW, Vinks AA,. Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration. Clin Pharmacokinet 2005; 44: 201-210. (Pubitemid 40188941)
    • (2005) Clinical Pharmacokinetics , vol.44 , Issue.2 , pp. 201-210
    • Mouton, J.W.1    Vinks, A.A.2
  • 63
    • 0031952586 scopus 로고    scopus 로고
    • Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
    • quiz 11-12.
    • Craig WA,. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-10; quiz 11-12.
    • (1998) Clin Infect Dis , vol.26 , pp. 1-10
    • Craig, W.A.1
  • 64
    • 13944278028 scopus 로고    scopus 로고
    • Use of pharmacokinetics and pharmacodynamics to optimize antimicrobial treatment of Pseudomonas aeruginosa infections
    • DOI 10.1086/426189
    • Burgess DS,. Use of pharmacokinetics and pharmacodynamics to optimize antimicrobial treatment of Pseudomonas aeruginosa infections. Clin Infect Dis 2005; 40: S99-S104. (Pubitemid 40270207)
    • (2005) Clinical Infectious Diseases , vol.40 , Issue.SUPPL.
    • Burgess, D.S.1
  • 65
    • 0032701245 scopus 로고    scopus 로고
    • Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycoside
    • Murry KR, McKinnon PS, Mitrzyk B, Rybak MJ,. Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycoside. Pharmacotherapy 1999; 19: 1252-1260.
    • (1999) Pharmacotherapy , vol.19 , pp. 1252-1260
    • Murry, K.R.1    McKinnon, P.S.2    Mitrzyk, B.3    Rybak, M.J.4
  • 66
    • 0021708980 scopus 로고
    • Role for dual individualization with cefmenoxime
    • Schentag JJ, Smith IL, Swanson DJ, DeAngelis C, Fracasso JE, Vari A, Vance JW,. Role for dual individualization with cefmenoxime. Am J Med 1984; 77: 43-50. (Pubitemid 15153297)
    • (1984) American Journal of Medicine , vol.77 , Issue.6 , pp. 43-50
    • Schentag, J.J.1    Smith, I.L.2    Swanson, D.J.3
  • 69
    • 0018935088 scopus 로고
    • Use of piperacillin, a semisynthetic penicillin, in the therapy of acute exacerbations of pulmonary disease in patients with cystic fibrosis
    • Prince AS, Neu HC,. Use of piperacillin, a semisynthetic penicillin, in the therapy of acute exacerbations of pulmonary disease in patients with cystic fibrosis. J Pediatr 1980; 97: 148-151. (Pubitemid 10033787)
    • (1980) Journal of Pediatrics , vol.97 , Issue.1 , pp. 148-151
    • Prince, A.S.1    Neu, H.C.2
  • 70
    • 0023675683 scopus 로고
    • Comparison of piperacillin alone versus piperacillin plus tobramycin for treatment of respiratory infections in children with cystic fibrosis
    • McCarty JM, Tilden SJ, Black P, Craft JC, Blumer J, Waring W, Halsey NA,. Comparison of piperacillin alone versus piperacillin plus tobramycin for treatment of respiratory infections in children with cystic fibrosis. Pediatr Pulmonol 1988; 4: 201-204.
    • (1988) Pediatr Pulmonol , vol.4 , pp. 201-204
    • McCarty, J.M.1    Tilden, S.J.2    Black, P.3    Craft, J.C.4    Blumer, J.5    Waring, W.6    Halsey, N.A.7
  • 71
    • 34447262551 scopus 로고    scopus 로고
    • Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers
    • DOI 10.1128/AAC.01477-06
    • Bulitta JB, Duffull SB, Kinzig-Schippers M, Holzgrabe U, Stephan U, Drusano GL, Sorgel F,. Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. Antimicrob Agents Chemother 2007; 51: 2497-2507. (Pubitemid 47047329)
    • (2007) Antimicrobial Agents and Chemotherapy , vol.51 , Issue.7 , pp. 2497-2507
    • Bulitta, J.B.1    Duffull, S.B.2    Kinzig-Schippers, M.3    Holzgrabe, U.4    Stephan, U.5    Drusano, G.L.6    Sorgel, F.7
  • 83
    • 84878314029 scopus 로고    scopus 로고
    • Ortho-McNeil-Janssen Pharmaceuticals, Inc.
    • Levaquin® Approved Package labeling, 2011, Ortho-McNeil-Janssen Pharmaceuticals, Inc.
    • (2011) Levaquin® Approved Package Labeling


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.